A team at Stanford Medicine led by Bali Pulendran has developed an experimental nasal spray vaccine that protects against COVID-19, influenza, bacterial pneumonia, and even common allergens in a single dose. Published in Science, the study showed vaccinated mice survived exposure to SARS-CoV-2, Staphylococcus aureus, and Acinetobacter baumannii for at least three months, while unvaccinated mice suffered severe lung inflammation and death.
Unlike traditional vaccines that target specific pathogens, the spray reprograms innate immune cells in the lungs to mount a broad defense within three days — compared to the typical two-week response. Viral levels in the lungs of vaccinated mice dropped 700-fold. The approach also reduced allergic reactions to house dust mites.
Pulendran estimates a universal respiratory vaccine could reach humans within five to seven years with adequate funding. Phase I safety trials in people are the next step.
